Skip to content
10-Q

Quarterly Report

Hepion Pharmaceuticals, Inc. CTRVP HEPA

0001493152-26-023136

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 29.12M sh
Shares Diluted Q1 2026 · Mar 31, 2026 11.62M sh
Shares Diluted Q1 2026 · Mar 31, 2025 2.84M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 $578.58K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.12M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.86M
Stockholders Equity Q1 2026 · Dec 31, 2025 $2.67M
Stockholders Equity Q1 2026 · Mar 31, 2025 $3.9M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$1.86M
Current Liabilities Q1 2026 · Mar 31, 2026 $735.57K
Current Liabilities Q1 2026 · Dec 31, 2025 $299.38K
Total Liabilities Q1 2026 · Mar 31, 2026 $848.75K
Total Liabilities Q1 2026 · Dec 31, 2025 $402.41K
Current Assets Q1 2026 · Mar 31, 2026 $2.71M
Current Assets Q1 2026 · Dec 31, 2025 $3.07M
Total Assets Q1 2026 · Mar 31, 2026 $2.71M
Total Assets Q1 2026 · Dec 31, 2025 $3.07M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.07
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.15
Eps Basic Q1 2026 · Mar 31, 2026 −$0.07
Eps Basic Q1 2026 · Mar 31, 2025 −$2.15
Sga Expense Q1 2026 · Mar 31, 2026 $728.51K
Sga Expense Q1 2026 · Mar 31, 2025 $1.26M
Rd Expense Q1 2026 · Mar 31, 2026 $70K
Rd Expense Q1 2026 · Mar 31, 2025 $22.24K
Net Income Q1 2026 · Mar 31, 2026 −$810.79K
Net Income Q1 2026 · Mar 31, 2025 −$6.11M
Operating Income Q1 2026 · Mar 31, 2026 −$798.51K
Operating Income Q1 2026 · Mar 31, 2025 −$1.28M